Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology (CYAD) announced that three abstracts were accepted for presentation at the 62nd American Society of Hematology Annual Meeting, occurring virtually from December 5-8, 2020. The abstracts will focus on the company’s CAR T candidates: the allogeneic CYAD-211 targeting BCMA, and the autologous CYAD-01 and CYAD-02 based on the NKG2D receptor. The findings will be published in the November issue of the journal Blood. CYAD-211 has received FDA clearance for its IND application, representing progress in CAR T therapy development for multiple myeloma and related cancers.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced its participation in three upcoming healthcare conferences in November 2020. The events are: Bryan, Garnier & Co. Virtual European Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17 at 2:55 p.m. ET, and SVB Leerink Oncology 1x1 Day on November 19. The company focuses on developing CAR T therapies for cancer, supported by the Walloon Region funding. Investors can find more details on Celyad's website.
Celyad Oncology (NASDAQ:CYAD) has announced a collaboration with MSD to conduct the Phase 1b KEYNOTE-B79 clinical trial. This trial will investigate the investigational allogeneic CAR T candidate, CYAD-101, in combination with MSD's KEYTRUDA® for treating refractory metastatic colorectal cancer patients. The collaboration aims to leverage the complementary mechanisms of both therapies, potentially addressing unmet needs in microsatellite stable disease. Encouraging results from the alloSHRINK trial provide a positive backdrop for this initiative.
Celyad Oncology, a clinical-stage biotechnology company, announced that CEO Filippo Petti will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 11:00 a.m. EDT. The event will be available for investors to listen to via a live webcast on the company's website, with an archived replay accessible for 30 days. Celyad focuses on developing CAR T cell therapies for cancer, including allogeneic and autologous candidates for treating hematological malignancies and solid tumors. The company, founded in 2007, is based in Belgium and New York.
Celyad Oncology (CYAD), a clinical-stage biotechnology company, will host a Research & Development webinar on September 29 at 11:00 a.m. EDT. The webinar will provide insights on its CAR T candidates, CYAD-101 for metastatic colorectal cancer and CYAD-211 for relapsed/refractory multiple myeloma. Dr. Richard Kim will discuss immuno-oncology treatments. Celyad's management will share updates on its pipeline and future directions. Interested participants can register for the live webcast through the company's website, where a replay will also be available post-event.
Celyad Oncology has announced an Open Market Sale Agreement with Jefferies LLC to sell up to $25 million of new American Depositary Shares (ADSs) through an at-the-market offering. The ADSs are priced at $9.91 each, representing a potential issuance of up to 2,777,777 shares. Proceeds from this offering will primarily support the company's CAR T cell therapy research and development initiatives. The offering is registered under a shelf registration statement effective as of September 4, 2020, with additional details available from Jefferies.
Celyad Oncology SA (CYAD) announced its participation in several conferences in September 2020, including the Wells Fargo 2020 Virtual Healthcare Conference and the H.C. Wainwright 22nd Annual Global Investment Conference. The company, based in Mont-Saint-Guibert, Belgium, focuses on developing CAR T cell therapies for cancer. Celyad is advancing both allogeneic and autologous therapy candidates for hematological malignancies and solid tumors. The press release includes a forward-looking statement about the expected initiation of a Phase 1 trial by year-end 2020.
Celyad Oncology announced that the FDA has granted permission for the Phase 1 clinical trial of CYAD-211, its first shRNA-based allogeneic CAR T candidate targeting BCMA for relapsed/refractory multiple myeloma. The trial is set to begin by the end of 2020. CYAD-211 is part of the CYAD-200 series and utilizes a unique shRNA technology platform. This marks a significant advancement for Celyad, demonstrating its ability to effectively develop multiple off-the-shelf CAR T therapies.
Celyad SA (Euronext & Nasdaq: CYAD) announced a corporate rebranding to Celyad Oncology, reflecting its commitment to pioneering CAR T cell therapies for cancer. This change accompanies the launch of a new logo and website, aimed at emphasizing the company’s progress in next-generation CAR T programs. CEO Filippo Petti highlighted the firm’s expertise and strategic focus on innovative cell therapies, particularly in the context of recent developments discussed at the American Society of Clinical Oncology conference.
Celyad (CYAD), a clinical-stage biopharmaceutical company, announced its participation in several virtual investor conferences in June 2020. The conferences include: Jefferies Virtual Healthcare Conference from June 2-4, William Blair 40th Annual Growth Stock Conference on June 10 at 2:00 p.m. CDT, and Kepler Cheuvreux Digital Belgian Life Science Day on June 22 at 3:10 p.m. CEST. Celyad is advancing CAR-T cell therapies targeting various cancers, with significant clinical trials ongoing for lead candidates CYAD-01 and CYAD-101.